Se-Aspirin
(Synonyms: Selenium-acetylsalicylic Acid) 目录号 : GC15267
A selenium-NSAID hybrid
Cas No.:1850293-95-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Se-Aspirin is a novel selenium-nonsteroidal anti-inflammatory drug (Se-NSAID) [1].
NSAIDs have demonstrated intestinal antineoplastic effects in various animal intestinal cancer models. Selenium (Se) compounds have attracted a vast interest as promising chemo-preventive agents. Several epidemiological studies have reported an inverse association between the nutritional Se status and cancer risk. Se functioned as chemo-preventive agent for cancer therapy in the past few years.
Se-Aspirin was a hybrid of selenium and a nonsteroidal anti-inflammatory drug. t Se-Aspirin reduced the viability of different cancer cell lines, particularly colorectal cancer (CRC) cells with the IC50 value of 3.4 μM. Se-Aspirin inhibited the cell cycle in G1 and G2/M phases and induced apoptosis by activating caspase 3/7 and PARP cleavage. Long-term exposure to Se-Aspirin has been reported to cause an increase in intracellular reactive oxygen species levels in CRC cells [1].
Reference:
[1] Plano D, Karelia D N, Pandey M K, et al. Design, synthesis, and biological evaluation of novel selenium (Se-NSAID) molecules as anticancer agents[J]. Journal of medicinal chemistry, 2016, 59(5): 1946-1959.
| Cas No. | 1850293-95-6 | SDF | |
| 别名 | Selenium-acetylsalicylic Acid | ||
| 化学名 | selenocyanic acid, 2-[[2-(acetyloxy)benzoyl]amino]ethyl ester | ||
| Canonical SMILES | O=C(C)OC1=CC=CC=C1C(NCC[Se]C#N)=O | ||
| 分子式 | C12H12N2O3Se | 分子量 | 311.2 |
| 溶解度 | ≤10mg/ml in ethanol;30mg/ml in DMSO;50mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2134 mL | 16.0668 mL | 32.1337 mL |
| 5 mM | 0.6427 mL | 3.2134 mL | 6.4267 mL |
| 10 mM | 0.3213 mL | 1.6067 mL | 3.2134 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。